Open Collections

UBC Faculty Research and Publications

Dabigatran for atrial fibrillation : Why we can not rely on RE-LY Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 80 provides a detailed analysis of the RE-LY trial, which compared dabigatran to warfarin in patients with atrial fibrillation. Conclusions: Licensing of dabigatran 150 mg BID for atrial fibrillation is premature, pharmacologically irrational and unsafe for many patients. The optimal dose of dabigatran for non-valvular atrial fibrillation is not yet clear. An independent audit of RE-LY is needed to check for irregularities in conduct, sources of bias and the cause of the unusually high incidence of intracranial hemorrhage in the warfarin arm. An independently conducted double-blind RCT comparing dabigatran with warfarin in patients with non-valvular atrial fibrillation is required. Taking antiplatelet drugs in combination with oral anticoagulants doubles the incidence of major bleeding events.

Item Metadata

Title
Dabigatran for atrial fibrillation : Why we can not rely on RE-LY
Alternate Title
Therapeutics Letter 80
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
2011-03
Description
Therapeutics Letter 80 provides a detailed analysis of the RE-LY trial, which compared dabigatran to warfarin in patients with atrial fibrillation. Conclusions: Licensing of dabigatran 150 mg BID for atrial fibrillation is premature, pharmacologically irrational and unsafe for many patients. The optimal dose of dabigatran for non-valvular atrial fibrillation is not yet clear. An independent audit of RE-LY is needed to check for irregularities in conduct, sources of bias and the cause of the unusually high incidence of intracranial hemorrhage in the warfarin arm. An independently conducted double-blind RCT comparing dabigatran with warfarin in patients with non-valvular atrial fibrillation is required. Taking antiplatelet drugs in combination with oral anticoagulants doubles the incidence of major bleeding events.
Subject
Anticoagulants; Atrial Fibrillation; Dabigatran; Intracranial Hemorrhages; Platelet Aggregation Inhibitors; Warfarin
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433659
URI
http://hdl.handle.net/2429/85069
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International